Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 51Lung Neoplasms 32Lymphoma 31Breast Neoplasms 29Multiple Myeloma 27Prostatic Neoplasms 25Melanoma 23Carcinoma, Non-Small-Cell Lung 23Leukemia, Myeloid, Acute 22Neoplasm Metastasis 21Ovarian Neoplasms 20Lymphoma, Non-Hodgkin 20Hematologic Neoplasms 20Glioma 18Pancreatic Neoplasms 17Urinary Bladder Neoplasms 16Neuroblastoma 15Colorectal Neoplasms 15Burkitt Lymphoma 15Carcinoma, Renal Cell 14Sarcoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Colonic Neoplasms 13Leukemia, Lymphocytic, Chronic, B-Cell 12Carcinoma 12Brain Neoplasms 12Triple Negative Breast Neoplasms 11Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Oropharyngeal Neoplasms 11

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasms, Squamous Cell × 30 days × Clear all
NCT05797246 2026-05-29

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡